Primeiro paciente de Parkinson dosado no estudo inicial do DNL151, potencial inibidor de LRRK2

SEPTEMBER 10, 2019 - First Parkinson’s Patient Dosed in Early Trial of DNL151, Potential LRRK2 Inhibitor.